Overview

A Dose-ranging Safety and Efficacy Study of Ecallantide to Reduce Surgical Blood Loss Volume

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and identify the optimal dose(s) of ecallantide in reducing blood loss in subjects undergoing coronary artery bypass surgery including the use of cardio pulmonary bypass.
Phase:
Phase 2
Details
Lead Sponsor:
Cubist Pharmaceuticals LLC
Treatments:
Ecallantide